These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 38605087)

  • 21. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
    Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
    Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising approaches in cancer immunotherapy.
    Taefehshokr N; Baradaran B; Baghbanzadeh A; Taefehshokr S
    Immunobiology; 2020 Mar; 225(2):151875. PubMed ID: 31812343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.
    Ku KS; Tang J; Chen Y; Shi Y
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
    Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
    Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.
    Dey S; Devender M; Rani S; Pandey RK
    Adv Protein Chem Struct Biol; 2024; 140():91-156. PubMed ID: 38762281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
    Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
    Roybal KT; Lim WA
    Annu Rev Immunol; 2017 Apr; 35():229-253. PubMed ID: 28446063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.
    Themeli M; Sadelain M
    Trends Mol Med; 2016 Apr; 22(4):271-273. PubMed ID: 26971630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
    Yang P; Meng M; Zhou Q
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
    Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
    Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
    Gjerstorff MF; Andersen MH; Ditzel HJ
    Oncotarget; 2015 Jun; 6(18):15772-87. PubMed ID: 26158218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Biology: Immunotherapy by Design.
    Brenner J; Cho JH; Wong NML; Wong WW
    Annu Rev Biomed Eng; 2018 Jun; 20():95-118. PubMed ID: 29345976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future approaches in immunotherapy.
    Rini B
    Semin Oncol; 2014 Oct; 41 Suppl 5():S30-40. PubMed ID: 25438998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.
    Saini SK; Rekers N; Hadrup SR
    Ann Oncol; 2017 Dec; 28(suppl_12):xii3-xii10. PubMed ID: 29092006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.